Yongke Zhang
Chief Scientific Officer IASO Therapeutics
Dr. Yongke Zhang is the Chief Scientific Officer at IASO BioTherapeutics, where he leads global R&D and translational strategy for next-generation cell and gene therapies. With more than two decades of experience spanning biologics discovery to clinical development, he has held senior scientific and leadership roles at OBiO Technology, Apexigen, Epitomics, and PDL BioPharma.
He earned his Ph.D. in Molecular and Cellular Biology from the University of Tokyo, following a Doctorate in Clinical Medicine from Peking University and a postdoctoral fellowship at DNAX/Schering-Plough Biopharma focused on oncology and cancer biology.
Seminars
Tuesday 24th February 2026
Navigating Ethics Approval for Investigator Initiated Trial Set-Up in China for Early Human Data
9:30 am
- Discuss the step-by-step process for obtaining ethics approval in China’s regulatory environment
- Highlight practical lessons from setting up IITs with local investigators to accelerate trial initiation
- Share how early human data from Chinese IITs can de-risk development and build credibility with global investors and partners
